These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1172 related articles for article (PubMed ID: 23918733)

  • 1. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
    Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
    Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
    Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
    J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
    Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
    Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
    Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
    Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
    Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
    J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes.
    Devic S; Mohammed H; Tomic N; Aldelaijan S; De Blois F; Seuntjens J; Lehnert S; Faria S
    Br J Radiol; 2016 Jun; 89(1062):20150388. PubMed ID: 27007269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of biological parameters in head and neck cancer based on in vivo distribution of
    Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W
    Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
    Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
    J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
    Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
    Dence CS; Ponde DE; Welch MJ; Lewis JS
    Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG?
    Roels S; Slagmolen P; Nuyts J; Lee JA; Loeckx D; Maes F; Stroobants S; Penninckx F; Haustermans K
    Acta Oncol; 2008; 47(7):1237-48. PubMed ID: 18654902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Analysis of Dynamic
    Schwartz J; Grkovski M; Rimner A; Schöder H; Zanzonico PB; Carlin SD; Staton KD; Humm JL; Nehmeh SA
    J Nucl Med; 2017 Jun; 58(6):911-919. PubMed ID: 28232611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.